Evotec announced on November 19, 2026, that its protein degradation partnership with Bristol Myers Squibb has received a second investigational new drug (IND) application acceptance from FDA, expanding the partnered molecular glue pipeline.¹ The second candidate, a cereblon E3 ligase modulator (CELMoD), is expected to enter a phase 1 clinical trial in 2027.¹
Key facts
- Partners: Evotec and Bristol Myers Squibb (collaboration begun 2018 with Celgene)
- Modality: Molecular glue degraders; cereblon E3 ligase modulators (CELMoDs)
- Milestone: Second investigational new drug application accepted by the FDA
- Second candidate: CELMoD; name, target, and indication not disclosed
- Expected start: Phase 1 trial in 2027
- First candidate: BMS-986506, in phase 1 in advanced clear cell renal cell carcinoma
- First candidate milestone: $10 million paid to Evotec on study initiation, March 2026
- Evotec platforms: PanOmics screening and PanHunter data analysis
- Partner contribution: Bristol Myers Squibb's CELMoD agent library
- Deal terms: Financial terms of the second acceptance not disclosed
“The progression of a second molecular glue candidate to IND acceptance demonstrates the repeatability and productivity of our discovery platform,” said Joanna Holbrook, PhD, chief scientific officer of Evotec, in a company press release.¹
What has the partnership produced so far?
The first candidate from the collaboration, BMS-986506, entered a phase 1 trial in advanced clear cell renal cell carcinoma in March 2026, triggering a $10 million milestone payment to Evotec.¹,² Bristol Myers Squibb initiated that first-in-human study.² Dr Holbrook said the second acceptance reinforces the value of the collaboration and strengthens confidence in the platform's potential to generate a growing pipeline of investigational candidates.¹
How are the companies working together?
The partnership began in 2018 with Celgene, now Bristol Myers Squibb, and was expanded in 2022.¹ It pairs Evotec's multi-omics screening, artificial intelligence (AI)-supported data analytics, and drug design capabilities with Bristol Myers Squibb's CELMoD agent library.¹ Evotec applies proteomics and transcriptomics at industrial scale through its PanOmics platform and analyzes the resulting data sets with PanHunter, which supports identification and advancement of CELMoDs into lead optimization, according to the company.¹
What are molecular glue degraders, and how do they work?
Molecular glue degraders induce interactions between an E3 ubiquitin ligase and a target protein, leading to ubiquitination and degradation of the recruited protein.¹ By inducing neomorphic interactions between cereblon and substrate proteins, CELMoDs enable pharmacological modulation of proteins that may not be amenable to traditional inhibitor or agonist approaches.¹
Conventional small molecules act by interfering with protein activity, a limitation to agonistic or antagonistic function that Evotec said renders about 90% of proteins undruggable.¹ A 2025 review in Biochemical Pharmacology describes targeted protein degradation as an approach that harnesses the ubiquitin-proteasome system to selectively eliminate specific proteins and thereby fully abolish their activities, in contrast with traditional inhibitors that transiently suppress protein activity.³ The review characterizes molecular glues as low molecular weight compounds that act as a molecular bridge between a target protein and an E3 ligase, enabling degradation without requiring classical binding pockets.³